JP2009540004A5 - - Google Patents

Download PDF

Info

Publication number
JP2009540004A5
JP2009540004A5 JP2009515526A JP2009515526A JP2009540004A5 JP 2009540004 A5 JP2009540004 A5 JP 2009540004A5 JP 2009515526 A JP2009515526 A JP 2009515526A JP 2009515526 A JP2009515526 A JP 2009515526A JP 2009540004 A5 JP2009540004 A5 JP 2009540004A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
carbamoyl
alkylamino
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540004A (ja
Filing date
Publication date
Priority claimed from US11/455,202 external-priority patent/US20070293575A1/en
Application filed filed Critical
Publication of JP2009540004A publication Critical patent/JP2009540004A/ja
Publication of JP2009540004A5 publication Critical patent/JP2009540004A5/ja
Pending legal-status Critical Current

Links

JP2009515526A 2006-06-15 2007-06-14 癌の貧血の治療のためのhifヒドロキシラーゼ阻害剤 Pending JP2009540004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/455,202 US20070293575A1 (en) 2006-06-15 2006-06-15 Compounds and methods for treatment of cancer-related anemia
PCT/US2007/014157 WO2007146438A1 (en) 2006-06-15 2007-06-14 Hif hydroxylase inhibitors for treatment of anemia of cancer

Publications (2)

Publication Number Publication Date
JP2009540004A JP2009540004A (ja) 2009-11-19
JP2009540004A5 true JP2009540004A5 (https=) 2011-03-10

Family

ID=38571332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515526A Pending JP2009540004A (ja) 2006-06-15 2007-06-14 癌の貧血の治療のためのhifヒドロキシラーゼ阻害剤

Country Status (7)

Country Link
US (2) US20070293575A1 (https=)
EP (1) EP2035000A1 (https=)
JP (1) JP2009540004A (https=)
CN (1) CN101500569A (https=)
AU (1) AU2007258213A1 (https=)
IL (1) IL195816A0 (https=)
WO (1) WO2007146438A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
EP2476669A1 (en) * 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
CN103497184A (zh) * 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
US8269008B2 (en) * 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2334682B1 (en) * 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2011048611A1 (en) 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
EP2649182A4 (en) * 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Compositions and methods for increasing erythropoietin (epo) production
WO2012097329A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing mean corpuscular volume
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
AU2013229922B2 (en) 2012-03-09 2017-09-28 Kyntra Bio, Inc. 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
KR20210130849A (ko) 2012-07-16 2021-11-01 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
CA2899024C (en) 2013-01-24 2022-01-04 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552263A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CA2528232C (en) * 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US20060183671A1 (en) * 2003-07-17 2006-08-17 Anne Angelillo-Scherrer Treatment of anemia
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
AU2006259352A1 (en) * 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2009540004A5 (https=)
JP2009540000A5 (https=)
JPH09124606A5 (https=)
KR950017970A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR950014072A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
US11680048B2 (en) Enhanced erythropoiesis and iron metabolism
KR950014069A (ko) 치환된 헤테로사이클릭 카복스아미드 에스테르, 이의 제조방법 및 약제로서의 이의 용도
US8530404B2 (en) Compounds and methods for treatment of cancer
AU2002362065B2 (en) Stabilization of hypoxia inducible factor (HIF) alpha
US20110015223A1 (en) Compounds and methods for treatment of cancer-related anemia
KR930019630A (ko) 셀폰아미도- 및 셀폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n-옥사이드, 이의 제조방법 및 약제로서 이의용도
US20100331362A1 (en) Treatment method for anemia
US7713986B2 (en) Compounds and methods for treatment of chemotherapy-induced anemia
KR970061869A (ko) 치환된 퀴놀린-2-카복실산 아미드, 이의 제조방법 및 약제로서의 이의 용도와 중간체
KR950032124A (ko) 설폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n- 옥사이드, 이의 제조방법 및 약제로서의 이의 용도
KR950032127A (ko) 치환된 헤테로사이클릭 카복스아미도에스테르, 이의 제조방법 및 약제로서의 이의 용도
US20140309256A1 (en) Therapeutic Method
KR950032125A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도